Navigation Links
Thomson Reuters Trademark Report Reveals New Challenges and Opportunities for Pharmaceutical Brands
Date:6/8/2011

NEW YORK, June 8, 2011 /PRNewswire/ -- According to a report published today by Thomson CompuMark, part of Thomson Reuters, the pharmaceutical industry has begun to adapt to stricter governmental brand name standards globally by rapidly increasing the number of trademarks it files for every new drug. These newer standards by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) are part of an effort to prevent look-alike/sound-alike pharmaceutical brand names and have led to increased rejection rates of new drug names.

The special report, Pharmaceutical Trademarks: How to Survive the Name Game – New Challenges and Opportunities for Pharmaceutical Companies, tracks trends in pharmaceutical trademark activity over the last 30 years, incorporates input from leading trademark attorneys and pharmaceutical industry executives and analyzes trademark initiatives at the FDA and EMA to shed light on this critical issue. Following are some of the key observations in the analysis:

  • FDA and EMA Rejection Rates Up: The long-term FDA trademark rejection rate is 30%, but it has increased to approximately 36% in recent years as the organization has adopted a more stringent approach to brand approvals. Combined, the FDA and EMA are rejecting 40%-50% of pharmaceutical trademarks each year.

  • More than 300% Increase in Global Pharma Trademark Filings: Between 1980 and 2010, the number of pharmaceutical trademarks filed increased by more than 300%. A total of 238,010 pharmaceutical trademarks were filed globally in 2010.

  • China Filing Most Pharmaceutical Trademarks in 2010: Chinese firms filed 36,105 pharmaceutical trademarks in 2010, more than any other region globally. China was followed by the US (27,545) and India (26,123). Some surprise emerging markets such as Vietnam, Venezuela and Turkey were also among the top 10 countries filing the most drug trademarks in 2010.

  • FDA Pilot Program Paves Way to Industry Best Practices: The FDA has initiated an industry-wide pilot program designed to improve consumer safety, streamline the review process and make regulatory decisions more transparent. By fostering collaboration with the pharmaceutical industry, this program has led to the development of several best practices that will contribute to the standardization of the trademark process.

"Pharmaceutical companies are facing more hurdles than ever to get new drugs to market, but, in the long run, the steps they are taking now to adapt to the new regulatory reality will improve safety and efficiency in the marketplace," said Martin Burke, managing director of Thomson CompuMark. "The key to that transition will be giving stakeholders access to the information they need to make informed decisions. We will continue to help the process by developing analytics that help brand owners reduce risk by properly vetting new trademark names on a global basis."

This report was compiled using Thomson CompuMark data to identify trends in pharmaceutical trademark applications and top filers by company and country. Thomson CompuMark Pharma Search reports allow pharmaceutical brand owners and their legal teams to screen trademark names globally, across different sources to review critical information quickly and efficiently, identifying potentially troublesome naming constructs before they ever become a hindrance to the new drug approval process.

To view the full report, Pharmaceutical Trademarks: How to Survive the Name Game – New Challenges and Opportunities for Pharmaceutical Companies go to: http://compumark.thomson.com/do/pharma_special_report.

Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 55,000 people and operates in over 100 countries. For more information, go to http://thomsonreuters.com.


'/>"/>
SOURCE Thomson Reuters
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Drug Combinations That May Cause Major Drug Interactions Common Among Seniors Who Take Antidepressants, According to Thomson Reuters Research
2. Higher Education Foundation in Brazil Seals Its Continued Relationship with Thomson Reuters for Academic Healthcare Content
3. Asia Pacific Pharma Companies Turning to High-Risk, High-Reward Drug Development, According to New Report from Thomson Reuters
4. Thomson Reuters Unveils Pharmacy Xpert Solution to Improve Medication Management for Hospital Pharmacists
5. Thomson Reuters Releases iPhone Support for Clinical Xpert Navigator
6. Federal Government Selects Thomson Reuters to Build Tool That Streamlines Comparative Effectiveness Research
7. Thomson Reuters Predicts Nobel Laureates
8. Morehead Memorial Hospital Goes Live with Thomson Reuters Clinical Xpert CareFocus
9. Thomson Reuters Expands CareNotes® Patient Education System to Support 15 Languages
10. Americans Confidence in Their Ability to Access and Pay for Healthcare Declines Significantly in May, According to Thomson Reuters Index
11. Global Pharmaceutical R&D Productivity Declining According to Thomson Reuters, CMR International
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 2016 Alzheimer Diagnostic Tests - Medical ... Medical Devices sector report , "Alzheimer Diagnostic Tests ... overview of Alzheimer Diagnostic Tests currently in pipeline ... the pipeline products with comparative analysis of the ... reviews major players involved in the pipeline product ...
(Date:2/8/2016)... LONDON , Feb.8, 2016 Aesthetic Devices ... GlobalData,s Medical Devices sector report, "Aesthetic Devices - Medical ... Devices currently in pipeline stage. This ... secondary and primary research by GlobalData,s team of industry ... be removed or altered based on the availability and ...
(Date:2/8/2016)... TOKYO and FAIRFIELD, N.J. ... (Otsuka) and Medimetriks Pharmaceuticals, Inc. (Medimetriks) today announced that ... exclusive development and commercialization rights for OPA-15406 in the ... agreement also provides manufacturing rights.  OPA-15406 is a topical, ... for atopic dermatitis. --> ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... are derived from a cluster of melanin when exposed to sunlight. Although most moles ... a lifetime of embarrassment. Historically, mole removal has involved a painful, often ...
(Date:2/8/2016)... ... 2016 , ... Guruji Mahendra Kumar Trivedi is offering 3 days of accelerated ... his birthday on February 10th. During this time, people can achieve better health, ... 250,000 people from over 40 different countries as an “ordinary man with an extraordinary ...
(Date:2/8/2016)... ... 08, 2016 , ... According to research by the National ... technicians to be certified or obtain continuing education. To increase patient awareness of ... Your Mouth?” campaign to inform dentists and patients about the possible lack of ...
(Date:2/7/2016)... , ... February 07, 2016 , ... Women's Excellence staff, ... Wear Red Day. National Wear Red Day is the first Friday each February ... disease and stroke cause 1 in 3 deaths among women each year – more ...
(Date:2/7/2016)... Scottsdale, AZ (PRWEB) , ... February 07, 2016 ... ... & Neck and Facial Plastics, has added Kybella® to his medical and surgical ... is a newly approved FDA injectable medication used as a non-surgical alternative for ...
Breaking Medicine News(10 mins):